Sutro Biopharma (STRO)

• Market cap: $74.3M
• 1 day: -9.6%
• 5 days: -14.86%
• 1 month: 11.89%
• 3 months: 8.09%
• 6 months: -34.56%
• Year to date: -54.56%
• 1 year: -80.29%
• 5 years: -91.96%
• 10 years: -94.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 244

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

1% less capital invested

Capital invested by funds: $40M [Q1] → $39.7M (-$285K) [Q2]

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

7.55% less ownership

Funds ownership: 73.36% [Q1] → 65.81% (-7.55%) [Q2]

11% less funds holding

Funds holding: 113 [Q1] → 101 (-12) [Q2]

28% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 43

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2
• Avg. target: $2.5
• High target: $3

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Wells Fargo Derek Archila	$3	Equal-Weight Maintained	12 Aug 2025
Piper Sandler Edward Tenthoff	$2	Overweight Upgraded	16 Jun 2025